FDA grants CytoDyn fast track designation for leronlimab (PRO 140) in metastatic triple-negative breast cancer, an unmet medical need

CytoDyn

7 May 2019 - CytoDyn today announced that the U.S. FDA has granted fast track designation to leronlimab (PRO140) for use in combination with carboplatin for the treatment of patients with CCR5-positive metastatic triple-negative breast cancer. 

Injection of the first patient in metastatic triple-negative breast cancer is anticipated to be imminent. Clinical trial sites include Quest Clinical Research in San Francisco, along with four additional trial sites, which are in the process of initiating patient enrollment, including: Northwestern University Medical School, Methodist Houston, Vanderbilt University and Sidney Kimmel Cancer Center.

Read CytoDyn press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Medicine , US , Fast track